178 related articles for article (PubMed ID: 33428943)
21. Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.
Cao H; Wang D; Gao R; Chen L; Feng Y
Biochem Biophys Res Commun; 2021 Feb; 541():56-62. PubMed ID: 33477033
[TBL] [Abstract][Full Text] [Related]
22. Sustained spindle-assembly checkpoint response requires de novo transcription and translation of cyclin B1.
Mena AL; Lam EW; Chatterjee S
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927403
[TBL] [Abstract][Full Text] [Related]
23. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
Lin F; Wen D; Wang X; Mahato RI
Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
[TBL] [Abstract][Full Text] [Related]
25. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer.
Chen L; Xu YX; Wang YS; Ren YY; Chen YM; Zheng C; Xie T; Jia YJ; Zhou JL
J Ethnopharmacol; 2024 Sep; 331():118265. PubMed ID: 38677579
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.
Kapur N; Mir H; Sonpavde GP; Jain S; Bae S; Lillard JW; Singh S
Cancer Lett; 2019 Jul; 454():1-13. PubMed ID: 30974114
[TBL] [Abstract][Full Text] [Related]
27. Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
Vellky JE; Bauman TM; Ricke EA; Huang W; Ricke WA
Prostate; 2019 Dec; 79(16):1811-1822. PubMed ID: 31503366
[TBL] [Abstract][Full Text] [Related]
28. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
29. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
30. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
31. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
Huang HC; Shi J; Orth JD; Mitchison TJ
Cancer Cell; 2009 Oct; 16(4):347-58. PubMed ID: 19800579
[TBL] [Abstract][Full Text] [Related]
32. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
Liu H; Song X; Hou J; Zhao Z; Chang J
DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms promoting escape from mitotic stress-induced tumor cell death.
Sinnott R; Winters L; Larson B; Mytsa D; Taus P; Cappell KM; Whitehurst AW
Cancer Res; 2014 Jul; 74(14):3857-69. PubMed ID: 24860162
[TBL] [Abstract][Full Text] [Related]
34. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
35. Detection of Androgen Receptor Variant 7 (
Hille C; Gorges TM; Riethdorf S; Mazel M; Steuber T; Amsberg GV; König F; Peine S; Alix-Panabières C; Pantel K
Cells; 2019 Sep; 8(9):. PubMed ID: 31514447
[TBL] [Abstract][Full Text] [Related]
36. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of Xenopus p31(comet) potentiates mitotic checkpoint exit.
Mo M; Arnaoutov A; Dasso M
Cell Cycle; 2015; 14(24):3978-85. PubMed ID: 25892037
[TBL] [Abstract][Full Text] [Related]
38. Polysaccharides from Lentinus edodes prevent acquired drug resistance to docetaxel in prostate cancer cells by decreasing the TGF-β1 secretion of cancer-associated fibroblasts.
Zhang W; Tao N; Bai L
J Nat Med; 2023 Sep; 77(4):817-828. PubMed ID: 37354258
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments.
Yu L; Shang ZF; Abdisalaam S; Lee KJ; Gupta A; Hsieh JT; Asaithamby A; Chen BP; Saha D
Nucleic Acids Res; 2016 Oct; 44(18):8842-8854. PubMed ID: 27568005
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri-microRNA-129 maturation.
Wu C; Miao C; Zhou S; Chang PA; He B; Zhou X; Tang Q
Environ Toxicol; 2024 Jun; 39(6):3734-3745. PubMed ID: 38546343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
